Bersacapavir - Janssen Sciences Ireland UC
Alternative Names: JNJ-379; JNJ-56136379; JNJ-6379Latest Information Update: 10 Apr 2024
At a glance
- Originator Janssen Sciences Ireland UC
- Developer Janssen Research & Development; Janssen Sciences Ireland UC
- Class Amides; Antivirals; Fluorinated hydrocarbons; Organic sulfur compounds; Pyrroles; Small molecules
- Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 13 Feb 2024 Janssen Research & Development completes a phase II clinical trials in Hepatitis B (Treatment-naive, Combination therapy) in Germany, Canada, France, Japan, Russia, Spain, Taiwan, Turkey, United Kingdom, USA (PO) (NCT04439539) (EudraCT2019-004978-26)
- 09 Jan 2024 Janssen completes the phase II INSIGHT trial for Hepatitis B (Combination therapy, In adults, In the elderly) in Belgium, France, Germany, Italy, New Zealand, Poland, Canada, United Kingdom and USA (PO) (EudraCT2019-004475-39) (NCT04585789)
- 17 Apr 2023 Janssen Research & Development completes a Phase-II clinical trials in Hepatitis B (Combination therapy) in Japan, New Zealand, Poland and Taiwan (SC) (NCT04667104)